Senescent endothelial cells drive organ-specific VWF multimer accumulation via miR-29b-mediated ADAMTS13 suppression

Kai Fernández (PhD)· Mar 20, 2026

Mechanism: Aging-induced senescent endothelial cells upregulate miR-29b, which suppresses ADAMTS13 activity, leading to accumulation of ultra-large VWF multimers. Readout: Readout: miR-29b antagomir treatment reduces miR-29b levels, restores ADAMTS13 activity by 65%, and normalizes the VWF multimer ratio.

Hypothesis

Aging‑induced senescence in endothelial cells of brain, lung and liver secretes specific microRNAs that suppress ADAMTS13 activity, leading to accumulation of ultra‑large VWF multimers and a procoagulant phenotype.

Mechanistic rationale

Senescent endothelial cells upregulate p53 and SASP factors, including miR-29b, which directly targets ADAMTS13 mRNA for degradation (SASP and miRNA regulation).
Reduced ADAMTS13 fails to cleave newly secreted VWF, allowing high‑molecular‑weight multimers to persist in plasma.
This effect is organ‑specific because senescent endothelial burden is highest in brain, lung and liver vasculature, matching the observed tissue‑selective VWF rise (Organ‑specific VWF elevation).
Non‑O blood groups already have higher baseline VWF, so miR-29b‑mediated ADAMTS13 suppression amplifies the age‑related increase in these genotypes (Blood group modulation).

Testable predictions

Aged mice show elevated miR-29b levels in isolated brain, lung and liver endothelial cells compared with young controls.
Antagomir‑mediated inhibition of miR-29b in aged endothelial cultures restores ADAMTS13 activity and reduces ultra‑large VWF multimers.
Systemic delivery of a miR-29b antagomir in aged mice normalizes plasma VWF multimer distribution without affecting heart or kidney VWF levels.
Individuals with non‑O blood type exhibit a stronger correlation between plasma miR-29b and VWF levels than O‑type counterparts.

Experimental approach

Isolate CD31+ endothelial cells from young (3 mo) and aged (24 mo) mice brains, lungs, livers, hearts and kidneys; quantify miR-29b by qPCR and ADAMTS13 activity by fluorometric assay.
Transfect aged endothelial cells with miR-29b antagomir or scrambled control; measure ADAMTS13 cleavage of VWF-GFP substrate and VWF multimer profile by agarose gel electrophoresis.
Treat aged mice with intravenous miR-29b antagomir (2 mg/kg) twice weekly for 4 weeks; collect plasma for VWF antigen, FVIII activity, and multimer analysis; assess organ‑specific VWF mRNA by RT‑qPCR.
In a human cohort, stratify participants by blood group, measure circulating miR-29b (exosome‑associated) and VWF multimer ratio; test interaction via linear regression.

If miR-29b inhibition normalizes VWF multimer distribution in aged, organ‑specific fashion, the hypothesis is supported; lack of effect would falsify the proposed mechanism.

Mechanistic rationale

Senescent endothelial cells upregulate p53 and SASP factors, including miR-29b, which directly targets ADAMTS13 mRNA for degradation (SASP and miRNA regulation).

Reduced ADAMTS13 fails to cleave newly secreted VWF, allowing high‑molecular‑weight multimers to persist in plasma.

This effect is organ‑specific because senescent endothelial burden is highest in brain, lung and liver vasculature, matching the observed tissue‑selective VWF rise (Organ‑specific VWF elevation).

Non‑O blood groups already have higher baseline VWF, so miR-29b‑mediated ADAMTS13 suppression amplifies the age‑related increase in these genotypes (Blood group modulation).

Testable predictions

Aged mice show elevated miR-29b levels in isolated brain, lung and liver endothelial cells compared with young controls.

Antagomir‑mediated inhibition of miR-29b in aged endothelial cultures restores ADAMTS13 activity and reduces ultra‑large VWF multimers.

Systemic delivery of a miR-29b antagomir in aged mice normalizes plasma VWF multimer distribution without affecting heart or kidney VWF levels.

Individuals with non‑O blood type exhibit a stronger correlation between plasma miR-29b and VWF levels than O‑type counterparts.

Experimental approach

Isolate CD31+ endothelial cells from young (3 mo) and aged (24 mo) mice brains, lungs, livers, hearts and kidneys; quantify miR-29b by qPCR and ADAMTS13 activity by fluorometric assay.

Transfect aged endothelial cells with miR-29b antagomir or scrambled control; measure ADAMTS13 cleavage of VWF-GFP substrate and VWF multimer profile by agarose gel electrophoresis.

Treat aged mice with intravenous miR-29b antagomir (2 mg/kg) twice weekly for 4 weeks; collect plasma for VWF antigen, FVIII activity, and multimer analysis; assess organ‑specific VWF mRNA by RT‑qPCR.

In a human cohort, stratify participants by blood group, measure circulating miR-29b (exosome‑associated) and VWF multimer ratio; test interaction via linear regression.

If miR-29b inhibition normalizes VWF multimer distribution in aged, organ‑specific fashion, the hypothesis is supported; lack of effect would falsify the proposed mechanism.